Patients entered into a clinical trial of TAVR and patients in two registries were evaluated for possible subclinical leaflet thrombosis in their bioprosthetic valves. 40% of the patients in the TAVR trial and 13% of registry patients were found to have such thrombosis. The risk was lower in patients anticoagulated with warfarin. Therpeutic antico
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transcatheter
September 30, 2015
In an interview filmed at the 2015 STS Annual Meeting in San Diego, California, Tom Nguyen speaks with Michael Reardon, Chief of Cardiac Surgery at the Methodist DeBakey Heart & Vascular Center in Houston, TX.
September 29, 2015
Vinnie Bapat of Guys and St. Thomas’ Hospital, London, UK, discusses the Edwards FORTIS device, a transcatheter mitral valve device.
September 24, 2015
Neil Moat of the Royal Brompton Hospital, London, UK, gives a talk on transcatheter mitral valve implantation.
September 23, 2015
The authors conducted a propensity-matched analysis of outcomes and costs associated with TAVR vs. SAVR procedures in patients considered either intermediate risk (STS PROM 4-8%) or high risk (STS PROM >8%) within the Commonwealth of Virginia.
September 18, 2015
This study describes activity and outcomes for both standard aortic valve implantation and transcatheter aortic valve implantation (TAVI) in England and Wales in the TAVI era. The study demonstrates that both standard aortic valve implantation and TAVI acitivity have increased since TAVI was first performed in the United Kingdom.
September 15, 2015
Alec Vahanian of Bichat Hospital, Paris, France, provides an overview of transcatheter mitral valve repair.
September 4, 2015
Short- and mid-term outcomes of TAVR for nonagenarian (>90 years) patients in the PARTNER-1 trial were assessed for 531 pts. MACE occurred in 35% including stroke in 3.6%. Important paravalvular leak occurred in 1.4%. 30-day mortality was 4% and 3-year mortality was 48%, which compared to 44% in a matched population. QOL stabilized at 6 months
September 3, 2015
The authors of this study compared quality of life in patients at increased surgical risk who underwent either transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR).
August 26, 2015
Vinod Thourani, Michael Mack, Wilson, Szeto, Eric Roselli, and Gorav Ailawadi discuss percutaneous mitral valve repair at the 2015 STS Annual Meeting.